- Home
- TWST
as 06-20-2025 4:00pm EST
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 1.8B | IPO Year: | 2018 |
| Target Price: | $49.10 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $27.12 - $60.90 | Next Earning Date: | 08-01-2025 |
| Revenue: | $347,680,000 | Revenue Growth: | 25.30% |
| Revenue Growth (this year): | 22.58% | Revenue Growth (next year): | 17.71% |
Stock Insider Trading Activity of Twist Bioscience Corporation (TWST)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cho Dennis | TWST | See Remarks | Jun 16 '25 | Sell | $33.48 | 94 | $3,146.65 | 104,967 | |
| Green Paula | TWST | SVP of Human Resources | Jun 6 '25 | Sell | $31.75 | 853 | $27,082.75 | 127,895 | |
| Cho Dennis | TWST | See Remarks | Jun 6 '25 | Sell | $31.75 | 257 | $8,159.75 | 104,967 | |
| WERNER ROBERT F. | TWST | Chief Accounting Officer | Jun 6 '25 | Sell | $31.75 | 225 | $7,143.75 | 49,966 | |
| WERNER ROBERT F. | TWST | Chief Accounting Officer | May 23 '25 | Sell | $27.73 | 839 | $23,263.79 | 49,966 | |
| Leproust Emily M. | TWST | Chief Executive Officer | May 21 '25 | Sell | $29.75 | 2,802 | $83,351.09 | 649,630 | |
| Cho Dennis | TWST | See Remarks | May 21 '25 | Sell | $29.75 | 531 | $15,795.66 | 104,967 | |
| WERNER ROBERT F. | TWST | Chief Accounting Officer | May 21 '25 | Sell | $29.75 | 242 | $7,198.77 | 49,966 | |
| Finn Patrick John | TWST | President and COO | May 21 '25 | Sell | $29.75 | 1,877 | $55,835.12 | 240,783 | |
| Laponis Adam | TWST | Chief Financial Officer | May 21 '25 | Sell | $29.75 | 936 | $27,843.19 | 106,018 |
Latest Twist Bioscience Corporation News
TWST Breaking Stock News: Dive into TWST Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 days ago
Here's Why We're Not At All Concerned With Twist Bioscience's (NASDAQ:TWST) Cash Burn Situation
MT Newswires
a month ago
Twist Bioscience Expands Element Biosciences Partnership for End-to-End NGS Tools
Business Wire
a month ago
Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions
Business Wire
a month ago
Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference
Business Wire
a month ago
Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insider Monkey
a month ago
Twist Bioscience Corporation (TWST): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential
MT Newswires
a month ago
Twist Bioscience, Ginkgo Bioworks Renegotiate Contract for DNA Technology, Assets
Business Wire
a month ago
Twist Bioscience and Ginkgo Bioworks Revise Collaboration
Compare TWST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TWST Twist Bioscience Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.